BTIG Maintains Buy on MDxHealth, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 58.8%

Neg 58.8% Neu 0% Pos 0%

BTIG analyst Mark Massaro maintains MDxHealth (NASDAQ:MDXH) with a Buy and lowers the price target from $7 to $4.

Comments

No comments yet. Be the first!